Varlilumab (INN;[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.[2] It is an anti-CD27 antibody and helps activate T-cells.[3]
This drug was developed by Celldex Therapeutics.
It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.[4] In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours[5]
^World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
^Statement On A Nonproprietary Name Adopted By The USAN Council - Varlilumab, American Medical Association.
^Melão A (June 2017). "Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows".
^Clinical trial number NCT02270372 for "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer" at ClinicalTrials.gov
^Clinical trial number NCT02335918 for "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors" at ClinicalTrials.gov
Varlilumab (INN; development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an...
being conducted for new targeted treatments, including: atezolizumab, varlilumab, durvalumab, avelumab, LAG525, MBG453, TRC105, and savolitinib. Chemotherapy...
cells its expression has been correlated with the secretion of IFNγ. Varlilumab is an IgG1 antibody that binds to CD27 and is an experimental cancer treatment...
Global Information